The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Contribution of neoadjuvant chemotherapy and radiation therapy (intensity-modulated radiation therapy with concurrent chemotherapy versus stereotactic body radiation therapy alone) on tumor volume regression in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma: A single institution experience.
 
Jacob K. Jamison
No Relationships to Disclose
 
Hope Cho
No Relationships to Disclose
 
Michael S. May
No Relationships to Disclose
 
Lyndon Luk
No Relationships to Disclose
 
Milana Flusberg
No Relationships to Disclose
 
Mariya Kobi
No Relationships to Disclose
 
Volkan Beylergil
No Relationships to Disclose
 
Ksenia Skorohodova
No Relationships to Disclose
 
Alexander G Raufi
No Relationships to Disclose
 
David Paul Horowitz
Research Funding - Varian Medical Systems (Inst)
 
Michael D. Kluger
No Relationships to Disclose
 
Samuel M Pan
No Relationships to Disclose
 
Lisa A. Kachnic
Consulting or Advisory Role - New B Innovation
Research Funding - Varian Medical Systems (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Beth Schrope
No Relationships to Disclose
 
Susan Elaine Bates
No Relationships to Disclose
 
Ruth Aroon White
No Relationships to Disclose
 
Ryan H. Moy
No Relationships to Disclose
 
Linda Wu
No Relationships to Disclose
 
John A. Chabot
No Relationships to Disclose
 
Gulam Abbas Manji
Honoraria - Celgene; Cend Therapeutics; Exelixis; Roche/Genentech
Consulting or Advisory Role - Cend Therapeutics; Exelixis; Ipsen; Roche/Genentech
Research Funding - Arcus Biosciences (Inst); BiolineRx (Inst); Merck (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene; Exelixis; Roche/Genentech